Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

被引：0

作者：

Dummer, R. ^{[1
]}

Ascierto, P. A. ^{[2
]}

Gogas, H. ^{[3
]}

Arance, A. ^{[4
]}

Mandala, M. ^{[5
]}

Liszkay, G. ^{[6
]}

Garbe, C. ^{[7
]}

Schadendorf, D. ^{[8
]}

Krajsova, I. ^{[9
,10
]}

Gutzmer, R. ^{[11
]}

Sileni, V. Chiarion ^{[12
]}

Dutriaux, C. ^{[13
]}

de Groot, J. W. B. ^{[14
]}

Yamazaki, N. ^{[15
]}

Loquai, C. ^{[16
]}

de Parseval, L. A. ^{[17
]}

Pickard, M. ^{[18
]}

Sandor, V. ^{[19
]}

Robert, C. ^{[20
]}

Flaherty, K. T. ^{[21
]}

机构：

[1] Univ Hosp Zurich Dermatol, Dept Dermatol, Zurich, Switzerland

[2] Ist Nazl Tumori Fdn Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy

[3] Natl & Kapodestrian Univ Athens, Laikon Hosp, Dept Internal Med, Athens, Greece

[4] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[5] Papa Giovanni XXIII Canc Ctr Hosp, Dept Oncol & Haematol, Bergamo, Italy

[6] Natl Inst Oncol, Dept Dermatol, Budapest, Hungary

[7] Eberhard Karls Univ Tubingen, Div Dermatooncol, Dept Dermatol, Tubingen, Germany

[8] Univ Hosp Essen, Dept Dermatol, Heidelberg, Germany

[9] Univ Hosp Prague, Dept Dermatooncol, Prague, Czech Republic

[10] Charles Univ Prague, Med Fac 1, Prague, Czech Republic

[11] Hannover Med Sch, Dept Dermatol & Allergy, Skin Canc Ctr, Hannover, Germany

[12] Oncol Inst Veneto IRCCS, Melanoma Canc Unit, Padua, Italy

[13] Hop St Andre, Dept Oncol Dermatol, Ctr Hosp Univ Bordeaux, Bordeaux, France

[14] Dept Med Oncol, Isala, Zwolle, Netherlands

[15] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[16] Univ Med Ctr, Dept Dermatol, Mainz, Germany

[17] Novartis Pharma AG, Translat Clin Oncol, Basel, Switzerland

[18] Array BioPharma Inc, Biostat & Data Management, Boulder, CO USA

[19] Array BioPharma Inc, Med Affairs, Boulder, CO USA

[20] Inst Gustave Roussy, Dept Med, Villejuif, France

[21] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1215O

引用

页数：2

共 50 条

[31] Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.
Dummer, Reinhard
Flaherty, Keith
Robert, Caroline
Arance, Ana Maria
De Groot, Jan Willem
Garbe, Claus
Gogas, Helen
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
Pickard, Michael D.
Zohren, Fabian
Edwards, Michelle L.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +
[33] Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Ascierto, Paolo A.
Dummer, Reinhard
Gogas, Helen J.
Flaherty, Keith T.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
de Groot, Jan Willem B.
Loquai, Carmen
Gollerkeri, Ashwin
Pickard, Michael D.
Robert, Caroline
EUROPEAN JOURNAL OF CANCER, 2020, 126 : 33 - 44
[34] BEACON CRC (binimetinib [BIM], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)ICTX with
Huijberts, Sanne
Schellens, Jan H. M.
Fakih, Marwan
Peeters, Marc
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Wasan, Harpreet Singh
Desai, Jayesh
Ciardiello, Fortunato
Yoshino, Takayuki
Maharry, Kati
Gollerkeri, Ashwin
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
Vogel, Arndt
Hegewisch-Becker, Susanna
Prager, Gerald
Folprecht, Gunnar
Stahl, Michael
Kopetz, Scott
Grothey, Axel
van Cutsetn, Eric
Yaeger, Rona
Wasan, Harpreet
Yoshino, Takayuki
Desai, Jayesh
Ciardello, Fortunato
Gollerkeri, Ashwin
Maharry, Kati
Loupakis, Fotios
Hong, Y.
Steeghs, Neeltje
Guren, Tormod Kyrre
Arkenau, Hendrik-Tobias
Garcia-Alfons, Pilar
Sandor, Victor
Christy-Bittel, Farina
Anderson, Lisa
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
[36] Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Riely, Gregory J.
Smit, Egbert F.
Ahn, Myung-Ju
Felip, Enriqueta
Ramalingam, Suresh S.
Tsao, Anne S.
Johnson, Melissa Lynne
Gelsomino, Francesco
Esper, Raymond M.
Nadal, Ernest
Offin, Michael
Provencio-Pulla, Mariano
Otterson, Gregory Alan
Dagogo-Jack, Ibiayi
Alcasid, Ann
Usari, Tiziana
Wilner, Keith D.
Pathan, Nuzhat
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Schadendorf, Dirk
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Yamazaki, Naoya
Queirolo, Paola
Guenzel, Carolin
Polli, Anna
Thakur, Mahgull
di Pietro, Alessandra
Ascierto, Paolo A.
EUROPEAN JOURNAL OF CANCER, 2024, 204
[38] Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) (vol 152, pg 116, 2021)
Gogas, Helen
Dummer, Reinhard
Ascierto, Paolo A.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
Yamazaki, Naoya
Loquai, Carmen
Queirolo, Paola
de Willem, Groot J.
Sellier, Abir T.
Suissa, Jeanne
Murris, Juliette
Gollerkeri, Ashwin
Robert, Caroline
Flaherty, Keith T.
EUROPEAN JOURNAL OF CANCER, 2022, 160 : 287 - 288
[39] Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz, Scott
Yoshino, Takayuki
Van Cutsem, Eric
Eng, Cathy
Kim, Tae Won
Wasan, Harpreet Singh
Desai, Jayesh
Ciardiello, Fortunato
Yaeger, Rona
Maughan, Timothy S.
Beyzarov, Elena
Zhang, Xiaoxi
Ferrier, Graham
Zhang, Xiaosong
Tabernero, Josep
NATURE MEDICINE, 2025, : 901 - 908
[40] Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
Jameson-Lee, Max
Ott, Patrick Alexander
Luke, Jason J.
Postow, Michael A.
Poklepovic, Andrew Stewart
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →